Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency

Journal of Infectious Diseases

Volumn 177, Issue 6, 1998, Pages 1451-1457

  Richards, C M ^a   Shimeld, C ^a   Williams, N A ^a   Hill, T J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HOST RESISTANCE; HUMAN CELL; IMMUNIZATION; IMMUNOSTIMULATION; LATENT VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031782358     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515302     Document Type: Article

References (15)

1. Nugent CT, McNally JM, Chervenak R, Wolcott RM, Jennings SR. Differences in the recognition of CTL epitopes during primary and secondary responses to herpes-simplex virus-infection in-vivo. Cell Immunol 1995;165:55-64.
2. Ghiasi H, Wechsler SL, Kaiwar R, Nesburn AB, Hofman FM. Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. J Virol 1995;69:334-40.
3. Manickan E, Francotte M, Kuklin N, et al. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4(+) Th1(+) T cells. J Virol 1995;69:4711-6.
4. Mestecky J, Eldridge JH. Targeting and controlled release of antigens for the effective induction of secretory antibody responses. Curr Opin Immunol 1991;3:492-5.
5. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. J Immunol 1979;122:1892-8.
6. Drew MD, Estrada-Correa A, Underdown BJ, McDermott MR. Vaccination by cholera toxin conjugated to a herpes simplex type 2 glycoprotein D peptide. J Gen Virol 1992;73:2357-66.
7. Takada A, Kida H. Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice. Arch Virol 1995;140:1629-35.
8. Clarke CJ, Wilson AD, Williams NA, Stokes CR. Mucosal priming of T lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant. Immunology 1991;72:323-9.
9. Wilson AD, Bailey M, Williams NA, Stokes CR. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet haemocyanin using cholera toxin as an adjuvant. Eur J Immunol 1991;21:2333-9.
10. Richards CM, Hill TJ, Williams NA. Enhancement of the immune response to non-replicating herpes simplex virus type-1 preparations by mucosal administration in the presence of cholera toxin. Vaccine 1997;15:1065-9.
11. Hill TJ, Field HJ, Blyth WA. Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. J Gen Virol 1975;28:341-53.
12. Jennings R, Quasim T, Sharrard RM, Hockley D, Potter CW. Zwitterionic detergent solubilisation of HSV-1 surface antigens. Arch Virol 1988;98:137-53.
13. Bailey M, Williams NA, Wilson AD, Stokes CR. Probit: weighted probit regression analysis. J Immunol Methods 1992;153:261-2.
14. Harper HM, Cochrane L, Williams NA. The role of small intestinal antigen presenting cells in the induction of T-cell reactivity to soluble protein antigens: association between aberrant presentation in the lamina propria and oral tolerance. Immunology 1996;89:449-56.
15. Beech JT, Bainbridge T, Thompson SJ. Incorporation of cells into an ELISA system enhances antigen driven lymphokine detection. J Immunol Methods 1997;205:163-8.